Yiquan Xu

No. 134 East Street
Fuzhou, 350001, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.

Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 31, 2026

GPX3 suppresses lung adenocarcinoma progression through HSPB1 ubiquitination and Hippo pathway activation.

GPX3 suppresses lung adenocarcinoma progression through HSPB1 ubiquitination and Hippo pathway activation.

Journal: Cell reports
Published: January 13, 2026

Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer.

Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer.

Journal: Cancer letters
Published: December 17, 2025

Safety and Efficacy of Aumolertinib as First-Line Treatment in EGFR-Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Phase II Study (ARISE Study).

Safety and Efficacy of Aumolertinib as First-Line Treatment in EGFR-Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Phase II Study (ARISE Study).

Journal: MedComm
Published: August 05, 2025

TMT1A inhibits lung adenocarcinoma progression by suppressing M2 macrophage polarization.

TMT1A inhibits lung adenocarcinoma progression by suppressing M2 macrophage polarization.

Journal: iScience
Published: June 24, 2025

Prognostic Value of Surgical Resection for Non-small-cell Lung Cancer Patients Comorbid With Minimal Pleural Effusion.

Prognostic Value of Surgical Resection for Non-small-cell Lung Cancer Patients Comorbid With Minimal Pleural Effusion.

Journal: Cancer control : journal of the Moffitt Cancer Center
Published: January 06, 2025

Correction: CHAC1 blockade suppresses progression of lung adenocarcinoma by interfering with glucose metabolism via hijacking PKM2 nuclear translocation.

Correction: CHAC1 blockade suppresses progression of lung adenocarcinoma by interfering with glucose metabolism via hijacking PKM2 nuclear translocation.

Journal: Cell death & disease
Published: December 09, 2024

Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.

Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.

Journal: Cancer control : journal of the Moffitt Cancer Center
Published: June 10, 2024

CHAC1 blockade suppresses progression of lung adenocarcinoma by interfering with glucose metabolism via hijacking PKM2 nuclear translocation.

CHAC1 blockade suppresses progression of lung adenocarcinoma by interfering with glucose metabolism via hijacking PKM2 nuclear translocation.

Journal: Cell death & disease
Published: May 26, 2024

STRIP2 is regulated by the transcription factor Sp1 and promotes lung adenocarcinoma progression via activating the PI3K/AKT/mTOR/MYC signaling pathway.

STRIP2 is regulated by the transcription factor Sp1 and promotes lung adenocarcinoma progression via activating the PI3K/AKT/mTOR/MYC signaling pathway.

Journal: Genomics
Published: February 22, 2024

Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.

Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.

Journal: Therapeutic advances in medical oncology
Published: December 12, 2023

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Journal: Thoracic cancer
Published: November 27, 2023
Showing 1-12 of 29

Last Updated: 09/26/2026